Akèy › Kansè nan tete › Kalifòni › San Diego
Etid klinik pou Kansè nan tete nan San Diego, CA
41 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote San Diego (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Ap rekriteFaz 3
- University of California San Diego Moores Cancer Center, San Diego
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Sharp Rees Stealy Medical Group Inc, San Diego
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- University of California San Diego Moores Cancer Center, San Diego
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Ap rekriteFaz 1/2
- Sharp Memorial Hospital, San Diego
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Ap rekriteFaz 2
- California Protons Cancer Therapy Center, San Diego
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Ap rekriteFaz 3
- California Protons Cancer Therapy Center, San Diego
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, La Jolla · 11 mi lwen
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- Moores Cancer Center, La Jolla · 11 mi lwen
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Ap rekriteVolontè an sante akeyi
- University of California San Diego, San Diego
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Ap rekriteFaz 3
- University Of California - San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Ap rekriteFaz 1/2
- University of California San Diego (UCSD) - Koman Family Outpatient Pavilion ? La Jolla, La Jolla · 11 mi lwen
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Scripps Health, San Diego
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- UCSD Moores Cancer Center, La Jolla · 11 mi lwen
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- University of California San Diego Medical Center, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · 11 mi lwen
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of California-San Diego, La Jolla · 11 mi lwen
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Scripps Health, La Jolla · 11 mi lwen
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- UC San Diego, San Diego
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
Ap rekriteEtid obsèvasyon
- University of California, San Diego, San Diego
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Kaiser Permanente-Rio San Diego, San Diego
- Kaiser Permanente-San Diego Zion, San Diego
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
Ap rekriteVolontè an sante akeyi
- University of California, San Diego, La Jolla · 11 mi lwen
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Ap rekriteFaz 2
- Scripps Health, San Diego
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- UC San Diego Medical Center - Hillcrest, San Diego
- California Protons Cancer Therapy Center, San Diego
- UC San Diego Moores Cancer Center, La Jolla · 11 mi lwen
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Ap rekriteFaz 1
- University of California, San Diego, La Jolla · 11 mi lwen
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- University of California San Diego - Moores Cancer Center, La Jolla · 11 mi lwen
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Kaiser Permanente-San Diego Zion, San Diego
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- University of California, San Diego; Moores Cancer Center, San Diego
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #101, La Jolla · 11 mi lwen
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- University of California San Diego, La Jolla · 11 mi lwen
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Ap rekriteFaz 1/2
- SHARP Healthcare, San Diego
Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
Ap rekriteFaz 2
- University of California, San Diego, La Jolla · 11 mi lwen
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Ap rekriteFaz 1/2
- Research Site, La Jolla · 11 mi lwen
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Ap rekrite
- UC San Diego Health, La Jolla · 11 mi lwen
Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance
Ap rekrite
- University of California, San Diego, La Jolla · 11 mi lwen
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, La Jolla · 11 mi lwen
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- University of California-San Diego, San Diego
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan San Diego
- Kansè Poumon ki pa ti selil48 etid
- Kansè (tout kalite)32 etid
- Kansè pwostat31 etid
- Kansè Metastatik30 etid
- Kansè kolorektal25 etid
- Kansè ovè24 etid
- Kansè pankreyas24 etid
- Kansè poumon23 etid
- Obèsite23 etid
- Ensifizyans kadyak23 etid
- Depresyon21 etid
- Melanom18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.